文献速递结核与非结核分枝杆菌

新型商用干扰素γ释放试验诊断结核感染的更新系统评价与荟萃分析

Diagnostic Performance of New Commercial Interferon-Gamma Release Assays for Mycobacterium tuberculosis Infection: An Updated Systematic Review and Meta-analysis.
PubMed 文献 · Clin Infect Dis · 2026-01-01

该更新系统评价与荟萃分析纳入39篇报告、8种新型商用IGRA,比较其与WHO推荐IGRA的敏感性、特异性和一致性。STANDARD E TB-Feron与QFT-Plus相比敏感性低2.8%、特异性低3.6%,kappa 0.802;LIAISON XL Analyzer特异性较QFT高0.1%,kappa 0.846。8种新检测中2种显示较好准确性与高一致性,总体证据确定性仍低。

要点

  • 8种新型IGRA中2种与WHO推荐IGRA一致性高、准确性较好
  • STANDARD E TB-Feron与QFT-Plus的kappa为0.802
  • LIAISON XL Analyzer与QFT的kappa为0.846

核心结论

  • 8种新型IGRA中2种显示较好的准确性与高一致性。
  • 总体证据确定性仍低,需高质量独立研究支持WHO政策更新。

研究设计与样本

  • 更新系统评价与荟萃分析,检索Medline、Embase、Web of Science、Cochrane CENTRAL及ICTRP。
  • 纳入横断面、队列和病例对照研究,使用QUADAS-2评估偏倚风险。
  • 从3039条记录中筛选出39篇报告(36篇发表),描述8种新型IGRA。

主要发现

  • STANDARD E TB-Feron与QFT-Plus相比敏感性低2.8%(95%CI -11.8%至6.2%),特异性低3.6%(95%CI -10.0%至2.7%)。

关键数值与推荐

  • 主要结局为新型IGRA与WHO推荐IGRA之间敏感性、特异性和一致性的合并差异。

临床怎么用

  • 临床选用新型IGRA时应关注其与WHO推荐IGRA的一致性证据。
  • STANDARD E TB-Feron和LIAISON XL Analyzer与QFT系列一致性较高,可作参考。

局限性

  • 总体证据确定性低,受偏倚风险和精确性不足影响。
  • 需在不同人群和环境中开展高质量独立研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The World Health Organization (WHO) currently endorses several commercial interferon-gamma release assays (IGRAs); policy updates are needed given the development of new tests. We conducted an updated systematic review and meta-analysis to compare sensitivity, specificity, and agreement of newly commercialized IGRAs with WHO-endorsed IGRAs. METHODS: Databases (Medline, Embase, Web of Science, Cochrane Central Register of Controlled Trials, and International Clinical Trials Registry Platform) were searched for studies published from 1 February 2021 to 30 September 2024, then again up to 16 December 2025. We included cross-sectional, cohort, and case-control studies and assessed risk of bias using QUADAS-2. The primary outcomes were pooled differences in sensitivity, specificity, and agreement between the new IGRAs and WHO-endorsed IGRAs. RESULTS: From 3039 records screened, 39 reports (36 published) describing 8 new IGRAs met eligibility: STANDARD E TB-Feron, LIAISON XL Analyzer (chemiluminescence immunoassay [CLIA]), Ichroma IGRA-TB, STANDARD F TB-Feron, VIDAS TB-IGRA, ASACIR.TB, Wantai CLIA, and AdvanSureI3 TB-IGRA. STANDARD E TB-Feron had nonsignificantly lower sensitivity (-2.8% [95% confidence interval {CI}, -11.8% to 6.2%]) and specificity (-3.6% [95% CI, -10.0% to 2.7%]), with kappa of 0.802 (95% CI, .729-.874]), compared to QFT-Plus. For LIAISON XL Analyzer, the specificity was 0.1% higher (95% CI, -6.2% to 6.4%) than QFT-Plus/QFT-GIT, with a pooled kappa of 0.846 (95% CI, .814-.878). CONCLUSIONS: Two of the 8 new tests reviewed showed promising accuracy and high agreement with WHO-endorsed IGRAs. The overall certainty of evidence remains low due to risk of bias and imprecision. High-quality, independent studies in diverse populations and settings are needed to inform future WHO recommendations for tuberculosis infection tests. Clinical Trials Registration. PROSPERO (CRD42024544404).

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Apriani L, Sidhu H, Korobitsyn A, et al. Diagnostic Performance of New Commercial Interferon-Gamma Release Assays for Mycobacterium tuberculosis Infection: An Updated Systematic Review and Meta-analysis. Clin Infect Dis. 2026. PMID: 41738388. doi:10.1093/cid/ciag102

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。